Search Results - "Turtle, C J"

Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion by Fiorenza, S., Zheng, Y., Purushe, J., Bock, T. J., Sarthy, J., Janssens, D. H., Sheih, A. S., Kimble, E. L., Kirchmeier, D., Phi, T. D., Gauthier, J., Hirayama, A. V., Riddell, S. R., Wu, Q., Gottardo, R., Maloney, D. G., Yang, J. Y. H., Henikoff, S., Turtle, C. J.

“…Chimeric antigen receptor-modified T cell (CAR-T) immunotherapy has revolutionised blood cancer treatment. Parsing the genetic underpinnings of T cell quality…”
Get full text

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies by Turtle, CJ, Riddell, SR, Maloney, DG

“…Chimeric antigen receptors (CARs) comprise a tumor‐targeting moiety, often in the form of a single chain variable fragment derived from a monoclonal antibody,…”
Get full text

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo by Sommermeyer, D, Hudecek, M, Kosasih, P L, Gogishvili, T, Maloney, D G, Turtle, C J, Riddell, S R

“…Adoptive T-cell therapy with gene-modified T cells expressing a tumor-reactive T-cell receptor or chimeric antigen receptor (CAR) is a rapidly growing field of…”
Get full text

Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma by Vari, F., Munster, D. J., Hsu, J. L., Rossetti, T. R., Mahler, S. M., Gray, P. P., Turtle, C. J., Prue, R. L., Hart, D. N. J.

“…Summary Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio‐process to purify CMRF‐56 monoclonal antibody…”
Get full text

HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 CAR‐T (MB‐106) FOR OUTPATIENT TREATMENT OF FOLLICULAR LYMPHOMA (FL)—RESULTS OF A SINGLE‐INSTITUTION TRIAL by Shadman, M., Yeung, C., Redman, M., Lee, S. Y., Lee, D. H., Qian, D. H., Ra, S., Ujjani, C. S., Dezube, B. J., Warren, E. H., Chapuis, A. G., Green, D. J., Cowan, A. J., Cassaday, R. D., Kiem, H., Poh, C., Smith, S. D., Milano, F., Gauthier, J., Hirayama, A. V., Turtle, C. J., Lynch, R. C., Gopal, A. K., Maloney, D. G., Till, B. G.

Get full text

Dendritic cells in tumor immunology and immunotherapy by Turtle, C J, Hart, D N J

“…Despite rapid advances in cancer therapeutics, relapsed disease due to failed immunosurveillance remains a major problem in many cancers. Dendritic cells are…”
Get more information

The immune response to breast cancer, and the case for DC immunotherapy by Allan, C.P., Turtle, C.J., Mainwaring, P.N., Pyke, C., Hart, D.N.J.

“…The long-held belief that breast cancer is a weakly immunogenic tumor and a poor candidate for immunotherapy should be reappraised. There is ample evidence for…”
Get full text

Q-fever associated with splenic infarction and an anti-cardiolipin antibody by TURTLE, C. J., COYLE, L. A., KOTSIOU, G.

Get full text

Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer by TURTLE, C. J., KEEFE, D. M. K., BELL, D., WHEELER, H., MA, D. D. F.

Get full text

Single step enrichment of blood dendritic cells by positive immunoselection by López, J.Alejandro, Bioley, Gilles, Turtle, Cameron J, Pinzón-Charry, Alberto, Ho, Chris S.K, Vuckovic, Slavica, Crosbie, Georgina, Gilleece, Maria, Jackson, David C, Munster, David, Hart, Derek N.J

“…Dendritic cells (DC) for cancer immunotherapy protocols are generated most commonly by in vitro differentiation of monocytes with exogenous cytokines (Mo-DC)…”
Get full text

A Distinct Subset of Self-Renewing Human Memory CD8 + T Cells Survives Cytotoxic Chemotherapy by Turtle, Cameron J., Swanson, Hillary M., Fujii, Nobuharu, Estey, Elihu H., Riddell, Stanley R.

“…The mechanisms that maintain human T cell memory during normal and perturbed homeostasis are not fully understood. The repeated induction of profound…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Shadman, M, Yeung, C, Redman, M, Lee, S Y, Lee, D H, Qian, D H, Ra, S, Ujjani, C S, Dezube, B J, Warren, E H, Chapuis, A G, Green, D J, Cowan, A J, Cassaday, R D, Kiem, H, Poh, C, Smith, S D, Milano, F, Gauthier, J, Hirayama, A V, Turtle, C J, Lynch, R C, Gopal, A K, Maloney, D G, Till, B G

Get full text

DC in multiple myeloma immunotherapy by Turtle, C.J., Brown, R.D., Joshua, D.E., Hart, D.N.J.

“…Therapy for patients with multiple myeloma (MM) is currently unsatisfactory and most patients eventually succumb to relapsed disease. DCs are a subset of…”
Get full text

Chimeric antigen receptor-modified T cells derived from defined CD8.sup.+ and CD4.sup.+ subsets confer superior antitumor reactivity in vivo by Kosasih, P L, Maloney, D G, Turtle, C J, Riddell, S R, Sommermeyer, D, Hudecek, M, Gogishvili, T

“…Adoptive T-cell therapy with gene-modified T cells expressing a tumor-reactive T-cell receptor or chimeric antigen receptor (CAR) is a rapidly growing field of…”
Get full text

Chimeric antigen receptor-modified T cells derived from defined CD8 super(+) and CD4 super(+) subsets confer superior antitumor reactivity in vivo by Sommermeyer, D, Hudecek, M, Kosasih, P L, Gogishvili, T, Maloney, D G, Turtle, C J, Riddell, S R

“…Adoptive T-cell therapy with gene-modified T cells expressing a tumor-reactive T-cell receptor or chimeric antigen receptor (CAR) is a rapidly growing field of…”
Get full text

Adoptive transfer of virus-specific and tumor-specific T cell immunity by Berger, Carolina, Turtle, Cameron J, Jensen, Michael C, Riddell, Stanley R

“…The adoptive transfer of T cells isolated or engineered to have specificity for diseased cells represents an ideal approach for the targeted therapy of human…”
Get full text

SAFETY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULTS AFTER CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR‐MODIFIED T‐CELL (CAR‐T) THERAPY by Shadman, M., Gauthier, J., Hay, K.A., Voutsinas, J.M., Milano, F., Li, A., Hirayama, A.V., Sorror, M.L., Cassaday, R.D., Till, B.G., Gopal, A.K., Sandmaier, B.M., Maloney, D.G., Turtle, C.J.

Get full text

HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY by Hirayama, A.V., Gauthier, J., Hay, K.A., Voutsinas, J.M., Wu, Q., Sheih, A., Purushe, J., Pender, B.S., Hawkins, R.M., Vakil, A., Phi, T., Steinmetz, R.N., Riddell, S.R., Maloney, D.G., Turtle, C.J.

Get full text

Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure by Gauthier, J., Hirayama, A.V., Hay, K.A., Lymp, J., Li, D., Sheih, A., Purushe, J., Pender, B.S., Hawkins, R.M., Vakil, A., Phi, T., Steinmetz, R.N., Riddell, S.R., Maloney, D.G., Turtle, C.J.

Get full text

Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy by Chung, Sarah H., Hughes, Grant, Koffman, Brian, Turtle, Cameron J., Maloney, David G., Acharya, Utkarsh H.

Get full text